Kohima News Paper

Duchenne Muscular Dystrophy Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Duchenne Muscular Dystrophy Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

September 27
01:45 2022
Duchenne Muscular Dystrophy Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

“Duchenne Muscular Dystrophy pipeline constitutes 60+ key companies continuously working towards developing 75+ Duchenne Muscular Dystrophy treatment therapies, analyzes DelveInsight”

 

It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Duchenne Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Duchenne Muscular Dystrophy Pipeline Report

  • DelveInsight’s Duchenne Muscular Dystrophy Pipeline analysis depicts the space with 75+ active players working to develop 75+ pipeline therapies.
  • The Duchenne Muscular Dystrophy pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
  • Key Duchenne Muscular Dystrophy Pipeline Companies such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutics, and many others
  • Duchenne Muscular Dystrophy Pipeline Therapies include Vamorolone, Delandistrogene moxeparvovec, Givinostat, WVE N531, Pamrevlumab, EDG 5506, Fordadistrogene movaparvovec, Renadirsen, SRP 5051, EN 001, TAS-205, SGT 001, CAP 1002, NS 089/NCNP 02, ENTR-601-44, SRP-9001, GNT 0004, SRP-5051, UX810, SGT-003, Exon 53, Exon 45, AVGN7, PGN EDO51, PGN EDODM1, PGN EDO53, PGN EDO44, PGN EDO45, ALT1102, BMN 351, AOC 1044, SRP-9001, GNT 0004, SRP-5053, SRP-5045, SRP-5052, SRP-5044, SRP-5050, SRP-5051, DYNE-251, SGT-003, RGX-202, Elamipretide, and many others.

 

To know more about the Duchenne Muscular Dystrophy Pipeline report, click here:-https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight

 

 

Duchenne Muscular Dystrophy Overview

Duchenne muscular dystrophy (DMD) is one of the most severe forms of inherited muscular dystrophies. It is the most common hereditary neuromuscular disease and does not exhibit a predilection for any race or ethnic group. Mutations in the dystrophin gene lead to progressive muscle fiber degeneration and weakness. This weakness may present initially with difficulty in ambulation but progressively advances to such an extent that affected patients are unable to carry out activities of daily living and must use wheelchairs. Cardiac and orthopedic complications are common, and death usually occurs in the twenties due to respiratory muscle weakness or cardiomyopathy. Current therapy is centered on treatment with glucocorticoids and physiotherapy to prevent orthopedic complications.

 

Duchenne Muscular Dystrophy Pipeline Insight Report

Duchenne Muscular Dystrophy Pipeline Insight 2022 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Duchenne Muscular Dystrophy pipeline landscape is provided which includes the disease overview and Duchenne Muscular Dystrophy treatment guidelines.

In the Duchenne Muscular Dystrophy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Duchenne Muscular Dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Duchenne Muscular Dystrophy Emerging Drugs under Different Phases of Clinical Development Include:-

  • Vamorolone: Santhera 
  • Givinostat: Italfarmaco 
  • Pamrevlumab: Fibrogen

 

Duchenne Muscular Dystrophy Pipeline Therapeutics Analysis

There are approx. 75+ key companies which are developing the therapies Duchenne Muscular Dystrophy. The companies which have their Duchenne Muscular Dystrophy drug candidates in the most advanced stage, i.e phase III include Roche.

 

DelveInsight’s Duchenne Muscular Dystrophy Pipeline Report covers around 75+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Download the Duchenne Muscular Dystrophy Pipeline Report to learn more about the emerging Duchenne Muscular Dystrophy emerging therapies at @ https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight

 

Duchenne Muscular Dystrophy Pipeline development activities

The Duchenne Muscular Dystrophy pipeline report provides insights into:

  • All of the companies that are developing therapies for the treatment of Duchenne Muscular Dystrophy with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Duchenne Muscular Dystrophy
  • Duchenne Muscular Dystrophy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Duchenne Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Duchenne Muscular Dystrophy

The Duchenne Muscular Dystrophy Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Scope of the Duchenne Muscular Dystrophy Pipeline Report

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Intravenous, Oral, Subcutaneous
  • Therapeutics Assessment By Molecule Type: Cell therapy, Peptide, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Glucocorticoid receptor agonists, Mineralocorticoid receptor antagonists, Histone deacetylase inhibitors, Connective tissue growth factor inhibitors, Dystrophin expression stimulants, RNA interference, Dystrophin replacements, Gene transference, Creatine kinase inhibitors, Myosin inhibitors, Protein synthesis modulators, Prostaglandin synthase inhibitors
  • Key Duchenne Muscular Dystrophy Companies: Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutic, and others.
  • Key Duchenne Muscular Dystrophy Pipeline Therapies: Vamorolone, Delandistrogene moxeparvovec, Givinostat, WVE N531, Pamrevlumab, EDG 5506, Fordadistrogene movaparvovec, Renadirsen, SRP 5051, EN 001, TAS-205, SGT 001, CAP 1002, NS 089/NCNP 02, ENTR-601-44, SRP-9001, GNT 0004, SRP-5051, UX810, SGT-003, Exon 53, Exon 45, AVGN7, PGN EDO51, PGN EDODM1, PGN EDO53, PGN EDO44, PGN EDO45, ALT1102, BMN 351, AOC 1044, SRP-9001, GNT 0004, SRP-5053, SRP-5045, SRP-5052, SRP-5044, SRP-5050, SRP-5051, DYNE-251, SGT-003, RGX-202, Elamipretide, and others.

 

Request for Sample PDF Report to know more about Duchenne Muscular Dystrophy drugs and therapies –https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight

 

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Duchenne Muscular Dystrophy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Duchenne Muscular Dystrophy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Delandistrogene moxeparvovec: Roche
  9. Mid Stage Products (Phase II)
  10. SRP 5051: Sarepta Therapeutics
  11. Early Stage Products (Phase I/II)
  12. WVE N531: Wave Life Sciences
  13. Early Stage Products (Phase I)
  14. EDG 5506: Edgewise Therapeutics
  15. Inactive Products
  16. Duchenne Muscular Dystrophy Key Companies
  17. Duchenne Muscular Dystrophy Key Products
  18. Duchenne Muscular Dystrophy- Unmet Needs
  19. Duchenne Muscular Dystrophy- Market Drivers and Barriers
  20. Duchenne Muscular Dystrophy- Future Perspectives and Conclusion
  21. Duchenne Muscular Dystrophy Analyst Views
  22. Duchenne Muscular Dystrophy Key Companies
  23. Appendix

 

Download Sample PDF Report for Duchenne Muscular Dystrophy clinical trials advancements @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/